Seagen Inc logo

SGEN - Seagen Inc Share Price

$182.75 -3.0  -1.6%

Last Trade - 22/01/21

Large Cap
Market Cap £24.08bn
Enterprise Value £22.82bn
Revenue £1.36bn
Position in Universe 376th / 6630
Unlock SGEN Revenue
Relative Strength (%)
1m -8.14%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
286.8 336.8 418.1 482.3 654.7 916.7 2,161 1,800 +26.2%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, SeagenInc revenues increased from $626.9M to $1.57B. Net incometotaled $446.6M vs. loss of $184.5M. Revenues reflectRoyalty revenues increase from $66.2M to $809.9M, Netproduct sales increase of 53% to $706.5M. Net Incomereflects Investment and other income (loss), net increasefrom $2.3M (expense) to $18M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SGEN
Graphical History


SGEN Revenue Unlock SGEN Revenue

Net Income

SGEN Net Income Unlock SGEN Revenue

Normalised EPS

SGEN Normalised EPS Unlock SGEN Revenue

PE Ratio Range

SGEN PE Ratio Range Unlock SGEN Revenue

Dividend Yield Range

SGEN Dividend Yield Range Unlock SGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SGEN EPS Forecasts Unlock SGEN Revenue
Profile Summary

Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA or tucatinib, for treatment of certain metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancers. The Company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its pipeline includes ladiratuzumab vedotin, an antibody-drug conjugate (ADC) targeting LIV-1.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated July 15, 1997
Public Since March 7, 2001
No. of Shareholders: 63
No. of Employees: 1,605
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite , Nasdaq 100 ,
Exchange NASDAQ Global Select Market
Shares in Issue 180,306,390
Free Float (0.0%)
Eligible for
SGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SGEN
Upcoming Events for SGEN
Thursday 4th February, 2021 Estimate
Q4 2020 Seattle Genetics Inc Earnings Release
Wednesday 28th April, 2021 Estimate
Q1 2021 Seattle Genetics Inc Earnings Release
Frequently Asked Questions for Seagen Inc
What is the Seagen Inc share price?

As of 22/01/21, shares in Seagen Inc are trading at $182.75, giving the company a market capitalisation of £24.08bn. This share price information is delayed by 15 minutes.

How has the Seagen Inc share price performed this year?

Shares in Seagen Inc are currently trading at $182.75 and the price has moved by 58.43% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Seagen Inc price has moved by 35.5% over the past year.

What are the analyst and broker recommendations for Seagen Inc?

Of the analysts with advisory recommendations for Seagen Inc, there are there are currently 5 "buy" , 6 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Seagen Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Seagen Inc next release its financial results?

Seagen Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Seagen Inc dividend yield?

Seagen Inc does not currently pay a dividend.

Does Seagen Inc pay a dividend?

Seagen Inc does not currently pay a dividend.

When does Seagen Inc next pay dividends?

Seagen Inc does not currently pay a dividend.

How do I buy Seagen Inc shares?

To buy shares in Seagen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Seagen Inc?

Shares in Seagen Inc are currently trading at $182.75, giving the company a market capitalisation of £24.08bn.

Where are Seagen Inc shares listed? Where are Seagen Inc shares listed?

Here are the trading details for Seagen Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: SGEN
What kind of share is Seagen Inc?

Based on an overall assessment of its quality, value and momentum, Seagen Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Seagen Inc share price forecast 2021?

Shares in Seagen Inc are currently priced at $182.75. At that level they are trading at 10.81% discount to the analyst consensus target price of 0.00.

Analysts covering Seagen Inc currently have a consensus Earnings Per Share (EPS) forecast of 3.298 for the next financial year.

How can I tell whether the Seagen Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Seagen Inc. Over the past six months, the relative strength of its shares against the market has been -8.99%. At the current price of $182.75, shares in Seagen Inc are trading at 7.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Seagen Inc PE Ratio?

The Seagen Inc PE ratio based on its reported earnings over the past 12 months is 71.7. The shares are currently trading at $182.75.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Seagen Inc?

Seagen Inc's management team is headed by:

Clay Siegall - CHM
Marc Lippman - IND
Felix Baker - LED
David Gryska - IND
Todd Simpson - CFO
Vaughn Himes - CTO
John Orwin - IND
Jean Liu - EVP
Roger Dansey - OTH
Ted Love - DRC
Who are the major shareholders of Seagen Inc?

Here are the top five shareholders of Seagen Inc based on the size of their shareholding:

Baker Bros. Advisors LP Hedge Fund
Percentage owned: 26.22% (47.3m shares)
Capital International Investors Investment Advisor
Percentage owned: 10.34% (18.6m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 6.31% (11.4m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.03% (10.9m shares)
T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 4.96% (8.94m shares)
Similar to SGEN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.